total assets (36,494): $1,227.47T
real estate: $446.62T
commodities (16): $379.78T
companies (20,668): $144.70T
currencies (112): $137.06T
govt bonds (177): $117.06T
cryptos (10,301): $2.25T
Sign up

Get the App

Scan with your phone to download. 35,000+ assets in your pocket.

Google Play QR code Google Play
App Store

The global leaderboard of wealth: $1.2 Quadrillion of Assets ranked by Market Cap

Companies

Alnylam Pharmaceuticals: An Unexpected Rival Trial Failure Improves The Core TTR Franchise Outlook

By seekingalpha.com · · 1 min read
Alnylam Pharmaceuticals: An Unexpected Rival Trial Failure Improves The Core TTR Franchise Outlook

Alnylam Pharmaceuticals: An Unexpected Rival Trial Failure Improves The Core TTR Franchise Outlook

Read the full article on seekingalpha.com

Comments 0

No comments yet. Be the first to share your thoughts!

← All News articles
—— As Seen On ——